RxDoctor Payments Data

Mario Haddad, MD

Internal Medicine · San Juan, PRNPI 1750386652

Payments from drug & device makers

$3,900in general payments, 2019–2025

Across 174 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$794
  • Johnson & Johnson$624
  • Boehringer Ingelheim$524
  • PBG Puerto Rico LLC$408
  • Sanofi-aventis U.S. LLC$320
  • E.r. Squibb & Sons, L.L.C.$285
  • plus $945 from 10 others

What the payments were for

  • Food & beverage$3,894100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,900 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$25,398
Medicare patients
99
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$145,439
JanumetSitagliptin Phos/Metformin Hcl135$98,062
FarxigaDapagliflozin Propanediol110$95,815
JardianceEmpagliflozin98$94,615
XareltoRivaroxaban90$94,163
SynjardyEmpagliflozin/Metformin Hcl149$92,767
SynthroidLevothyroxine Sodium593$73,542
JanuviaSitagliptin Phosphate53$53,778
TradjentaLinagliptin35$36,433
EntrestoSacubitril/Valsartan40$35,495
Janumet XrSitagliptin Phos/Metformin Hcl45$29,512
LantusInsulin Glargine,hum.Rec.Anlog252$25,569
OzempicSemaglutide23$25,187
Synjardy XrEmpagliflozin/Metformin Hcl32$24,540
TrulicityDulaglutide17$17,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Tradjenta, Synjardy Xr, Glyxambi$524$290,941376 claims
MerckJanumet, Januvia, Janumet Xr$263$181,352233 claims
AstraZenecaFarxiga, Brilinta$794$106,952125 claims
Johnson & JohnsonXarelto$624$94,16390 claims
Sanofi-aventis U.S. LLCLantus$320$25,569252 claims
Novo NordiskOzempic$25$25,18723 claims
GSKBreo Ellipta$139$5,78214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →